SEC FIlings Archives - Page 14 of 19

16 May

SEC FIlings

Quarterly report for quarter ending Mar 31, 2022

November 17, 2022
Posted by Jitendra

16 May

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

13 May

SEC FIlings

Registration of securities, business combinations

November 17, 2022
Posted by Jitendra

11 May

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

29 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

26 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

25 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

13 Apr

SEC FIlings

Prospectuses and communications, business combinations

November 17, 2022
Posted by Jitendra

11 Apr

SEC FIlings

Current report – Amendment

November 17, 2022
Posted by Jitendra

11 Apr

SEC FIlings

Current report

November 17, 2022
Posted by Jitendra

SEC FIlings

Quarterly report for quarter ending Mar 31, 2022

Prospectuses and communications, business combinations

Registration of securities, business combinations

Prospectuses and communications, business combinations

Prospectuses and communications, business combinations

Prospectuses and communications, business combinations

Prospectuses and communications, business combinations

Prospectuses and communications, business combinations

Current report – Amendment

Current report

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists